Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 254

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 8
Chunk 254
---
 share amounts)

    Year Ended December 31,

    2024

    2023

    2022

    Revenue
     
    $
    178,957

    $
    170,276

    $
    185,308

    Operating expenses

    Cost of revenue

    72,080

    75,553

    57,909

    Research and development

    102,953

    122,117

    141,756

    Sales and marketing

    84,759

    88,579

    95,603

    General and administrative

    72,806

    83,934

    88,527

    Amortization of intangible assets

    1,703

    1,699

    1,699

    Impairment of long-lived assets

    7,205

    25,429

    —

    Total operating expenses

    341,506

    397,311

    385,494

    Loss from operations

    (162,549
    )

    (227,035
    )

    (200,186
    )

    Interest and other income, net

    14,534

    15,531

    4,056

    Interest expense

    (11,580
    )

    (13,800
    )

    (4,238
    )

    Net loss

    (159,595
    )

    (225,304
    )

    (200,368
    )

    Add: Net loss attributable to noncontrolling interest

    103

    54

    177

    Net loss attributable to Adaptive Biotechnologies Corporation
     
    $
    (159,492
    )
     
    $
    (225,250
    )
     
    $
    (200,191
    )

    Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted
     
    $
    (1.08
    )
     
    $
    (1.56
    )
     
    $
    (1.40
    )

    Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted

    147,101,648

    144,383,294

    142,515,917

The accompanying